# Biotech Daily Digest — 2025-12-20

**7 items from 2 sources**

## Summary by Source

- Endpoints News: 3 items
- Fierce Biotech: 4 items


## Endpoints News

- **[White House unveils nine more ‘most favored nation’ deals](https://endpoints.news/white-house-unveils-nine-new-most-favored-nation-deals/)**  
  _Fri, 19 Dec 2025 19:19:36 +0000_  
  The White House on Friday announced new deals with nine major drugmakers, finalizing an end-of-year push by President Donald Trump to make good on his “most favored nation” pledge for lower medicine prices.

 Amgen, Boehringer ...

- **[Senators point fingers over who blocked the rare disease voucher reauthorization](https://endpoints.news/senators-point-fingers-over-who-blocked-the-rare-disease-voucher-reauthorization/)**  
  _Fri, 19 Dec 2025 15:43:21 +0000_  
  Sens. Bernie Sanders (I-VT) and Markwayne Mullin (R-OK) are not seeing eye to eye on why the Senate failed to pass legislation reauthorizing the FDA's rare pediatric priority review voucher program.

 Mullin took to the ...

- **[Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail](https://endpoints.news/altimmune-advances-in-mash-new-china-obesity-biotech-ipsen-phase-2-fail/)**  
  _Fri, 19 Dec 2025 15:41:31 +0000_  
  Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix

 Altimmune goes to Phase 3 in MASH: The drug developer's Phase 2 trial of pemvidutide, a GLP-1/glucagon agonist, failed in June. But based on a longer ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/ipsens-hopes-next-gen-rare-disease-drug-dashed-pivotal-ph-2-fail" hreflang="en">Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail</a>](https://www.fiercebiotech.com/biotech/ipsens-hopes-next-gen-rare-disease-drug-dashed-pivotal-ph-2-fail)**  
  _Dec 19, 2025 3:04pm_  
  Ipsen’s oral small molecule failed to reduce the progression of a genetic disease that gradually turns tendons and ligaments into bone, prompting the pharma to stop the study early.

- **[<a href="https://www.fiercebiotech.com/biotech/vc-aditum-bio-launches-new-biotech-foray-fosun-pharma" hreflang="en">VC Aditum Bio launches new biotech in business play with Fosun Pharma</a>](https://www.fiercebiotech.com/biotech/vc-aditum-bio-launches-new-biotech-foray-fosun-pharma)**  
  _Dec 19, 2025 10:49am_  
  Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the sole purpose of developing novel therapies in tandem with the Shanghai-based drugmaker.

- **[<a href="https://www.fiercebiotech.com/biotech/merck-turns-down-option-evaxions-gonorrhea-vaccine-prompting-danish-biotech-seek-other" hreflang="en">Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners</a>](https://www.fiercebiotech.com/biotech/merck-turns-down-option-evaxions-gonorrhea-vaccine-prompting-danish-biotech-seek-other)**  
  _Dec 19, 2025 10:14am_  
  Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish biotech’s chance to collect up to $592 million in biobucks.

- **[<a href="https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program" hreflang="en">Patient deaths prompt partial hold for Daiichi-Merck's global phase 3 ADC program</a>](https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program)**  
  _Dec 18, 2025 11:02am_  
  Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial.
